logo

RLMD

Relmada TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

RLMD Profile

Relmada Therapeutics, Inc.

A late-stage biotechnology company that addressing diseases of the central nervous system

Pharmaceutical
--
10/10/2019
NASDAQ Stock Exchange
17
12-31
Common stock
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134
--
Relmada Therapeutics, Inc., a privately held company, was incorporated in May 2004. The company is a clinical-stage biopharmaceutical company focused on developing drug candidates for the treatment of chronic pain. The company is focused on the development of d-methadone (dexmethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Methadone is a new chemical entity that may address areas of unmet medical need in the treatment of central nervous system (CNS) diseases and other diseases.